R Bio

R Bio is a South Korean biotechnology company specializing in the development of adult stem cell therapies and regenerative medicine. Formerly known as RNL Bio, the company focuses on autologous adipose-derived stem cell (ADSC) technologies for treating a variety of conditions, including osteoarthritis, Alzheimer's disease, and autoimmune disorders. R Bio operates research facilities and clinics, primarily in Asia, and has been a pioneer in the commercialization of stem cell banking and therapeutic applications. Despite historical regulatory and legal challenges, the company continues to advance its pipeline of cell-based treatments through its Biostar Stem Cell Research Institute. Its lead candidate, JointStem, has undergone late-stage clinical trials for the treatment of degenerative arthritis and is marketed in partnership with Nature Cell.